Navigation Links
Dartmouth researchers receive $5.9 million grant from NIH for lung research
Date:9/30/2013

Hanover, N.H.The National Institutes of Health (NIH) has awarded a $5.9 million grant to support an Institutional Development Award (IDeA) Lung Biology Center of Biomedical Research Excellence (COBRE) at the Geisel School of Medicine at Dartmouth.

For the past 10 years, COBRE funding has supported the Center's work, which has contributed not only to our understanding of cystic fibrosis and to the development of patented and patent-pending therapeutic approaches for treating the disease, but to other chronic lung diseases. Lung disease is the third most frequent cause of death in the United States.

Directed by Principal Investigator Bruce Stanton, PhD, professor of microbiology and immunology at Geisel, the Lung Biology Center draws on the expertise and dedication of more than 100 faculty, students, and research associates working in 32 laboratories.

"Continued federal funding for the Lung Biology Center is very important to the Geisel School of Medicine and I applaud Bruce Stanton for his leadership," says Duane Compton, PhD, senior associate dean for research and professor of biochemistry at Geisel. "He has built a center that translates the best basic science into clinical application, and which also supports core facilities that sustain our researchers."

With the federal budget sequester taking a toll on biomedical research nationally, this five-year grant award reflects recognition of the quality of the medical research being done at Dartmouth, and provides the resources necessary to support the core services and pilot programs that will enable the Center to continue its work.

"The Lung Biology Center has spearheaded the development and mentoring of a cadre of physician-scientists engaged in cystic fibrosis research," says Stanton. "Their approaches are closely aligned with the goals of the Dartmouth SYNERGY Program in Clinical and Translational Science, which focuses on moving therapeutic advances from the research bench to the patient's bedside."

"This NIH grant demonstrates the strength of Geisel's overall research enterprise, and the excellent discovery taking place around cystic fibrosis and other chronic lung diseases," says Wiley "Chip" Souba, MD, MBA, ScD, dean of Dartmouth's Geisel School of Medicine. "While the sequester is forcing research cuts at many universities, research funding to the medical school just reached an all-time high, with $140 million in total grant funding for fiscal year 2013."

The Lung Biology Center is one of four Dartmouth Centers receiving COBRE support from the National Institute of General Medical Sciences Institutional Development Award Program (IDeA). The others include Immunology, Quantitative Biomedical Sciences, and Molecular Epidemiology. All COBRE programs share expertise and experience with each other, with the New Hampshire-INBRE (IDeA Network of Biomedical Research Excellence), and with partner programs at the University of Vermont and the Mt. Desert Island Biological Laboratory in Maine.

The IDeA program builds research capacities in states that historically have had low levels of NIH funding by supporting basic, clinical, and translational research; faculty development; and infrastructure improvements.


'/>"/>

Contact: Derik Hertel
kenneth.d.hertel@dartmouth.edu
603-650-1211
The Geisel School of Medicine at Dartmouth
Source:Eurekalert

Related medicine news :

1. Dartmouth researchers investigate the cognitive effects of athlete head impacts
2. Mayo Clinic, Dartmouth-Hitchcock announce collaboration
3. Dartmouth medical research closes in on new tuberculosis vaccine
4. Leap in leukemia treatment reported by Dartmouth researchers
5. Dartmouth researchers test safety of Nivolumab in kidney cancer
6. Dartmouth researchers develop molecular switch that changes liquid crystal colors
7. NIH awards $20 million over 5 years to train next generation of global health researchers
8. Researchers develop a new cell and animal model of inflammatory breast cancer
9. Researchers uncover a viable way for colorectal cancer patients to overcome drug resistance
10. Researchers Find Gene Mutations That May Be a Key to Autism
11. Researchers find evidence of banned antibiotics in poultry products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... ... still in shock after receiving a $2,500 Academic Award from California Casualty . “This ... She thinks the coming week is going to be a very joyful for her classroom. ... students.” , The award will allow the 4th grade teacher at Tumwater Hill Elementary School ...
(Date:3/27/2017)... ... March 27, 2017 , ... ?Grow Healthy ... resolve the pending litigation between itself and 1800 Vending DBA Healthy You Vending. ... “I am thrilled to announce that we have now reached a settlement agreement ...
(Date:3/26/2017)... (PRWEB) , ... March 26, 2017 , ... ... worldwide to receive the RealSelf 100 Award, a prestigious award honoring the top ... procedures and to find and connect with doctors and clinics. , In 2016, ...
(Date:3/24/2017)... York, NY (PRWEB) , ... March 24, 2017 ... ... campaign: “Fighting Infection,” which will spark a conversation on the current obstacles facing ... the number of completely preventable deaths caused by these infections. , The ...
(Date:3/24/2017)... ... March 24, 2017 , ... Texas Physical Therapy Specialists (TexPTS) is ... 9618 Huebner Road. The clinic is the group’s 7th location in San Antonio and ... Higgins, PT, will provide care from the clinic, which opened March 22, 2017. ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... BOSTON , March 27, 2017 ... pharmaceutical company and Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), ... commercialization of innovative therapies based upon tetracycline chemistry, ... sarecycline for the treatment of moderate to severe ... Sarecycline is a once-daily, oral, narrow spectrum tetracycline-derived ...
(Date:3/27/2017)... 2017  Impax Laboratories, Inc. (NASDAQ: IPXL)today announced that ... Bisaro as Impax,s President and Chief Executive Officer ... 27, 2017. Mr. Bisaro will succeed J. Kevin ... Chief Executive Officer since December of 2016. ... experience, Mr. Bisaro, 56, is an accomplished global business ...
(Date:3/27/2017)... March 27, 2017  PhaseRx, Inc. (NASDAQ: PZRX), ... inherited liver diseases in children, today reported financial ... ended December 31, 2016 and provided an update ... continued to make progress during the fourth quarter ... from our non-human primate safety study, and with our ...
Breaking Medicine Technology: